The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Takhzyro lanadelumab OrphanAccelerated assessment | Takeda Pharmaceuticals International AG Ireland Branch | Angioedemas, Hereditary | 🇪🇺 EU 2018-11-22 | Order → |
| Ziextenzo pegfilgrastim Biosimilar | Sandoz GmbH | 🇪🇺 EU 2018-11-22 | Order → | |
| Apealea paclitaxel | Inceptua AB | Ovarian Neoplasms | 🇪🇺 EU 2018-11-20 | Order → |
| Buvidal buprenorphine | Camurus AB | Opioid-Related Disorders | 🇪🇺 EU 2018-11-20 | Order → |
| Fulphila pegfilgrastim Biosimilar | Biosimilar Collaborations Ireland Limited | 🇪🇺 EU 2018-11-20 | Order → | |
| Pelmeg pegfilgrastim Biosimilar | Mundipharma Corporation (Ireland) Limited | 🇪🇺 EU 2018-11-20 | Order → | |
| Vaborem meropenem;vaborbactam | Menarini International Operations Luxembourg S.A. | Urinary Tract Infections; Bacteremia; Bacterial Infections; Respiratory Tract Infections; Pneumonia; Pneumonia, Ventilator-Associated | 🇪🇺 EU 2018-11-20 | Order → |
| Emgality galcanezumab Additional monitoring | Eli Lilly Nederland B.V. | Migraine Disorders | 🇪🇺 EU 2018-11-14 | Order → |
| Symkevi tezacaftor;ivacaftor Orphan | Vertex Pharmaceuticals (Ireland) Limited | Cystic Fibrosis | 🇪🇺 EU 2018-10-31 | Order → |
| Gefitinib Mylan gefitinib Generic | Mylan Pharmaceuticals Limited | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2018-09-27 | Order → |
| Verzenios abemaciclib | Eli Lilly Nederland B.V. | Breast Neoplasms | 🇪🇺 EU 2018-09-26 | Order → |
| Imfinzi durvalumab | AstraZeneca AB | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2018-09-21 | Order → |
| Pelgraz pegfilgrastim Biosimilar | Accord Healthcare S.L.U. | 🇪🇺 EU 2018-09-21 | Order → | |
| Udenyca pegfilgrastim BiosimilarAdditional monitoring | ERA Consulting GmbH | 🇪🇺 EU 2018-09-21 | Order → | |
| Kigabeq vigabatrin | Orphelia Pharma S.A.S. | Spasms, Infantile; Epilepsies, Partial | 🇪🇺 EU 2018-09-20 | Order → |
| Lenalidomide Accord lenalidomide Generic | Accord Healthcare S.L.U. | Multiple Myeloma | 🇪🇺 EU 2018-09-20 | Order → |
| Mektovi binimetinib | Pierre Fabre Medicament | Melanoma | 🇪🇺 EU 2018-09-20 | Order → |
| Slenyto melatonin | RAD Neurim Pharmaceuticals EEC SARL | Sleep Initiation and Maintenance Disorders; Autistic Disorder | 🇪🇺 EU 2018-09-20 | Order → |
| Xerava eravacycline | PAION Pharma GmbH | Infection; Bacterial Infections | 🇪🇺 EU 2018-09-20 | Order → |
| Braftovi encorafenib | Pierre Fabre Medicament | Melanoma; Colorectal Neoplasms | 🇪🇺 EU 2018-09-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.